Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure

Journal of the American College of Cardiology

Volumn 26, Issue 2, 1995, Pages 438-445

  Dickstein, Kenneth ^a   Chang, Paul ^a   Willenheimer, Ronnie ^b   Haunsø, Stig ^c   Remes, Jouko ^d   Hall, Christian ^e   Kjekshus, John ^f  

^a Hjertelaget Research Foundation   (Norway)

^b MERCK RESEARCH LABORATORIES   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Rigshospitalet   (Denmark)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; ANGIOTENSIN ANTAGONIST; ANTICOAGULANT AGENT; ATRIAL NATRIURETIC FACTOR; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LOSARTAN; NORADRENALIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DYSPNEA; EXERCISE; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; BIPHENYL COMPOUNDS; CHRONIC DISEASE; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENALAPRIL; EXERCISE TEST; FEASIBILITY STUDIES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMIDAZOLES; LOSARTAN; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TREATMENT OUTCOME;

EID: 0029102699     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(95)80020-H     Document Type: Article

References (38)

1. Effect of the renin-angiotensin system on limb circulation and metabolism during exercise in patients with heart failure
2. Effects of enalapril in heart failure: a double-blind study of effects on exercise performance, renal function, hormones, and metabolic state
3. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure
4. Losartan in heart failure: hemodynamic effects and tolerability
5. Nonpeptide angiotensin II receptor antagonists: VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent
6. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of response to exogenous angiotensin I and II
7. DuP 753 is a specific antagonist for the angiotensin receptor
8. Nonpeptide angiotensin II receptor antagonists: studies with DUP 753 and EXP3174 in dogs
9. The broad substrate specificity of human angiotensin I converting enzyme
10. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting inhibitors: a double-blind, randomized, cross-over study
11. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure
12. Effects of enalapril on mortality in severe congestive heart failure
13. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure
14. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure
15. The continuing unethical use of placebo controls
16. A method for the determination of heart size by roentgenography (a heart volume index)
17. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure
18. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction
19. Assay of plasma catecholamines by liquid chromatography with electrochemical detection
20. Identification and plasma concentrations of the N-terminal fragment of atrial natriuretic factor in man
21. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure: assessment by acute renin and converting enzyme inhibition
22. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure
23. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition
24. Neuvohumoral activation during exercise in congestive heart failure
25. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left ventricular dysfunction (SOLVD)
26. Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure
27. Cough and ACE inhibitors
28. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough: a research review
29. Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure
30. Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril
31. Acute and long-term effects of captopril in exercise cardiac performance and exercise capacity in congestive heart failure
32. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
33. Sample sizes for event rate equivalence trials using prior information
34. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure
35. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril
36. Short-term effects following withdrawal from enalapril in patients with heart failure [abstract]
37. Determinants of drug response in severe chronic heart failure. Action of vasoconstrictor forces during vasodilator therapy
38. Molecular biology and heterogeneity of angiotensin II receptors